The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Liver safety of febuxostat compared with allopurinol in. For patients with recurrent flares of gout, tophi, urate crystal arthropathy, and renal stones, uratelowering therapies ults, including allopurinol and febuxostat are the firstline treatment. We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopurinol, a purine base. We performed a primary casenoncase analysis in which the disproportionality between arf and all other adrs was expressed as the reporting odds ratio ror 95% confidence interval ci for febuxostat and allopurinol vs. The differences between both febuxostat treatment groups and the. Nuflash study, and reported that in addition to reducing uric acid ua to a significantly lower level than allopurinol, febuxostat showed a. The confirms study reported comparable efficacy of febuxostat 40 mg compared with allopurinol 300 mg febuxostat 40 mg. Febuxostattreated patients were permitted an index medication dose of 40 mg or 80 mg the only 2 available doses. Main results were replicated in this sensitivity analyses without any attenuation of estimates for dose and.
The new england journal of medicine n engl j med 353. Patients who in the opinion of the investigator have a high genetic risk for allopurinol hypersensitivity syndrome ahs unless they have been found to be negative for hla b5801. Comparative effectiveness of allopurinol versus febuxostat for. Administration of febuxostat or allopurinol resulted. Patients with mild renal dysfunction ckd stage 1 or 2 and those. Comparing febuxostat to allopurinol in the treatment of. The sensitivity analyses confirmed the disproportionality for these two ults. This table shows sensitivity analyses with propensityscore adjusted analyses limited to patients with gout. Febuxostat compared with allopurinol in patients with. Zyloprim allopurinol works well to prevent gout attacks and is cheaper than some alternatives, but it takes a few weeks to start working. Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid b a hilmi, mbbs, mmed, m i asmahan, mbbs, mmed, a rosman, md, mrcp international islamic university malaysia, internal medicine, jalan hospital, kuantan, pahang 25100 malaysia case report this article was accepted. Uloric febuxostat is a medication you take once daily for gout, but it takes a few weeks to kick in. Switching from allopurinol to febuxostat for the treatment.
In studies of the effect of allopurinol on cv riskevents allopurinol has found to be protective so whether febuxostat is different is a point to clarify. Regarding net clinical benefits, febuxostat and allopurinol are comparable. The longterm management of gout requires reduction of serum urate levels and this is most often achieved with use of xanthine oxidase inhibitors, such as allopurinol. Sensitivity analyses for propensityscore adjusted association of allopurinol or febuxostat with hazard of incident dementia limited to patients with gout. The most common doses were 300 mgday or lower dose for allopurinol and 40. Comparative effectiveness of allopurinol versus febuxostat. Therefore, the present study evaluated the longterm efficacy and tolerability of febuxostat in hd patients after switching from allopurinol. Gout is a form of inflammatory arthritis that is caused by hyperuricaemia or high amounts of uric acid in the blood.
If a rash occurs while taking allopurinol, immediate discontinuation of. Pdf for decades allopurinol has been used as a xanthine oxidase inhibitor for treatment of hyperuricemia and gout. On the other hand, the switch from allopurinol 200 mgday to febuxostat 20 mgday resulted in an increase serum ua level. Intensive urate lowering therapy of febuxostat compared to allopurinol on cardiovascular risk in patients with gout forward. The net clinical benefits of febuxostat versus allopurinol. Febuxostat adenuric for chronic symptomatic gout nps. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. These results show that the mg dose of allopurinol and the 10mg dose of febuxostat have essentially equivalent effect. Cardiovascular safety of febuxostat or allopurinol in patients with. Aloprim and febuxostat uloric along with changes in diet and lifestyle, to. Febuxostat compared with allopurinol in patients new england. Compare headtohead ratings, side effects, warnings, dosages, interactions and.
Methods in a retrospective cohort study using 20062012 medicare claims data, we included patients newly treated with allopurinol or febuxostat baseline period of 183 days without either medication. Febuxostat and allopurinol combination works better in gout. Use of newly available febuxostat in a case of chronic. Febuxostat, allopurinol, gout, metaanalysis introduction hyperuricemia is defined as a serum urate sua level exceeding the limit of urate solubility 6. Due to the widespread use of these ults especially in patients with impaired renal function, assessment of the associated renal risk is essential. The primary outcome was achieved by 53% of patients receiving 80 mg of febuxostat, 62% of those receiving 120 mg of febuxostat, and 21% of those receiving allopurinol p allopurinol is used in the treatment of high uric acid levels associated with gout, kidney stones, and cancer treatment. Of patients taking febuxostat at 40 or 80 mg daily, 45% and 67%, respectively, reached the primary endpoint compared with 42% of those taking allopurinol 200300 mg daily. Kevin deane discusses confirms trial data comparing the efficacy and safety of febuxostat in the treatment of hyperuricemia in gout with that of allopurinol. Febuxostat compared with allopurinol in patients with hyperuricaemia and gout. Comparative effectiveness of urate lowering with febuxostat versus. All structured data from the file and property namespaces is available under the creative commons cc0 license.
Four of the 507 patients in the two febuxostat groups 0. Previous history of failure to reach target uric acid levels despite therapy with allopurinol at dose. However, these results should be interpreted with caution, as the study designs did not reflect best clinical practice because allopurinol dosage was not titrated to optimal effect. In the registration trials for febuxostat there were concerns about a cardiovascular cv safety signal. Intensive urate lowering therapy of febuxostat compared to. African americans are twice as likely as caucasians to develop gout, but they are less likely to be treated with uratelowering therapy ult. In the eu, it is indicated in adults for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred. Comparison of febuxostat and allopurinol for hyperuricemia. Summary in the majority of patients with gout, the mainstay of treatment for decreasing serum uric acid concentrations has been with inhibitors of xanthine oxidase xo, such as allopurinol zyloprim. Febuxostat was more effective than allopurinol at the currently used doses 40 mgday for febuxostat in 83% users and 300 mgday or lower for. Compare allopurinol vs febuxostat comprehensive analysis. A realworld study of switching from allopurinol to febuxostat in a health plan database. Files are available under licenses specified on their description page.
Acute kidney injury associated with febuxostat and. Adverse events were according to the medical dictionary for regulatory activities meddra. Since febuxostat is not a structural analogue of either purines or pyrimidines, it does not interfere with the activity of these other pathways. This article is from bmc musculoskeletal disorders, volume. Furthermore, african americans typically present with more comorbidities associated with gout, such as hypertension, obesity, and renal impairment. Febuxostat and allopurinol combination works better in. A realworld study of switching from allopurinol to. However, few studies have examined the longterm efficacy and tolerability of febuxostat after switching from allopurinol in hemodialysis hd patients. Comparative efficacy and safety of uratelowering therapy. When in accumulated amounts, uric acid tends to form monosodium urate crystals that localize around the joints and periarticular tissue.
Background febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout. Allopurinol two common very common prescriptions for gout and how they work. Febuxostat may be better than allopurinol in lowering urate. Colcrys colchicine is a secondchoice treatment for gout attacks. The differences in the mechanisms of action between. Direct url citation appears in the printed text and is provided in the html and pdf versions of this article on the. We previously conducted a comparative study of febuxostat and allopurinol the nihon university working group study of febuxostat and usual allopurinol therapy for patients with hyperuricemia. We determined the efficacy and safety of ult with febuxostat or allopurinol in african american subjects. To assesses the efficacy of a relatively new drugfebuxostat in management of gout and its. Comparison of febuxostat and allopurinol for hyperuricemia in. African americans are twice as likely as caucasians to develop gout, but they. Although febuxostat has been widely used for lowering uric acid levels because of its renal safety compared with allopurinol, data on the hepatic safety of febuxostat is limited.
This retrospective study utilized 2009 to 2012 medical and pharmacy claims and laboratory data from a. Due to the potential consequences of arf, physicians should. Febuxostat is the first new xanthine oxidase inhibitor since allopurinol and was licensed for use in 2008. When in accumulated amounts, uric acid tends to form monosodium urate crystals that localize around the joints and periarticular tissue, causing an inflammatory response and in the long term, tissue damage. To assess the comparative effectiveness of febuxostat and allopurinol in reducing serum urate sua levels in a realworld u. We have since corrected these errors and the correct publishers have. Unlike allopurinol, the prototypical xanthine oxidase inhibitor that is the cornerstone therapy for chronic gout, febuxostat does. The prevalence of hyperuricemia and gout has been increasing, but the comparative effectiveness and safety of different treatments remain uncertain. Listing a study does not mean it has been evaluated by the u. A diagnose of gout disorder on within 30 months prior to the index date. Pdf comparison between allopurinol and febuxostat in. Febuxostat vs allopurinol and placebo in subjects with hyperuricaemia and gout. Febuxostat the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Objective to assess the comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in elderly.
225 1093 1170 1324 396 1480 669 147 1154 1459 348 810 683 417 1417 289 1464 1552 1195 406 198 1155 28 1323 1401 1301 208 1552 309 630 1143 1382 1062 1168 1437 684 853 878